BW
ABUS icon

Boaz Weinstein’s Arbutus Biopharma ABUS Stock Holding History

Boaz Weinstein’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-347,885
Closed -$1.67M – 393
2025
Q4 		$1.67M Sell
347,885
-330,886
-49% -$1.49M 0.05% 176
2025
Q3 		$3.08M Sell
678,771
-581,358
-46% -$2.14M 0.08% 135
2025
Q2 		$3.89M Buy
1,260,129
+280,613
+29% +$932K 0.09% 118
2025
Q1 		$3.42M Buy
979,516
+91,523
+10% +$305K 0.09% 90
2024
Q4 		$2.9M Buy
887,993
+211,566
+31% +$778K 0.07% 105
2024
Q3 		$2.6M Buy
676,427
+25,000
+4% +$95.9K 0.05% 134
2024
Q2 		$2.01M Buy
651,427
+277,967
+74% +$834K 0.03% 141
2024
Q1 		$964K Buy
+373,460
New +$967K 0.02% 169

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Boaz Weinstein's ABUS Position: Q1 2026 in Review

Boaz Weinstein sold out of Arbutus Biopharma (ABUS) in Q1 2026, closing a stake of 347,885 shares — an estimated $1.67M sold.

Boaz Weinstein first reported a position in ABUS in Q1 2024 and held it in 8 quarters. The position peaked at $3.89M in Q2 2025. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • Boaz Weinstein reported no remaining Arbutus Biopharma position as of Q1 2026 after selling out during the quarter.
  • Boaz Weinstein sold 347,885 Arbutus Biopharma shares in Q1 2026, an estimated $1.67M.
  • Boaz Weinstein first reported a position in Arbutus Biopharma in Q1 2024 and held it in 8 quarters.
  • Boaz Weinstein's Arbutus Biopharma position peaked at $3.89M in Q2 2025.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Saba Capital Management's 13F filing for Q1 2026, filed 15 May 2026.